Featured Research

from universities, journals, and other organizations

Major Herpes Vaccine Trial Launched In Women

Date:
November 21, 2002
Source:
NIH/National Institute Of Allergy And Infectious Diseases
Summary:
A pivotal efficacy trial of an experimental vaccine designed to prevent genital herpes in women began enrolling volunteers this week. The study will determine the vaccine's ability to prevent genital herpes disease in women who are free of two common types of herpes simplex viruses (HSV): HSV-1 and HSV-2.

A pivotal efficacy trial of an experimental vaccine designed to prevent genital herpes in women began enrolling volunteers this week. The study will determine the vaccine's ability to prevent genital herpes disease in women who are free of two common types of herpes simplex viruses (HSV): HSV-1 and HSV-2. The trial will eventually enroll 7,550 women in at least 16 sites in the United States. It is the result of a partnership between the National Institute of Allergy and Infectious Diseases (NIAID) and the vaccine's manufacturer, GlaxoSmithKline Biologicals (GSK), headquartered in Belgium.

"This vaccine trial is an excellent example of a mutually beneficial collaboration between the public and private sectors," says NIAID Director Anthony S. Fauci, M.D. "More than one million new cases of genital herpes are diagnosed in the United States each year. The physical and psychological toll taken by this sexually transmitted disease is considerable. Successful public-private collaborations such as this one will take us closer to our goal of reducing the spread of genital herpes."

Previous efficacy trials of the GSK vaccine were conducted in smaller numbers of men and women who did not have genital herpes but whose sexual partners were known to be infected. For reasons still not well understood, the vaccine prevented herpes disease in more than 70 percent of HSV-1 and HSV-2 negative women but had no clear effect in men. The results of these earlier Phase III trials are reported in this week's edition of The New England Journal of Medicine.

Finding thousands of HSV-negative women for the new trial will be a significant challenge, says Pamela McInnes, D.D.S, M.Sc.(Dent.), deputy director of NIAID's Division of Microbiology and Infectious Diseases. Between 50 and 80 percent of Americans are infected with HSV-1, typically during childhood, and about 1 in 5 people over age 12 is infected with HSV-2. The majority of those infected do not realize it, however, because symptoms of herpes disease can be mild or non-existent.

Symptoms following infection typically include blisters and then ulcers around the mouth or genitals. The virus may be transmitted through sexual or other skin-to-skin contact, and can even be spread when the infected person shows no symptoms. Once in the body, HSV migrates to nerve cells and remains there permanently. From time to time, an infected person may experience a herpes outbreak, but recurrences are typically less severe than the first occurrence. HSV can cause devastating illness in infants born to infected women, and the virus has been identified as a risk factor for the spread of HIV/AIDS in adults.

In the new trial, volunteers will be randomly assigned to receive either the candidate vaccine or a vaccine against hepatitis A. (This gives all participants a chance to be protected from a disease.) Neither the volunteers nor the researchers will know which vaccine a volunteer received until the close of the trial. Volunteers will be vaccinated at the start of the trial and at 1 and 6 months after the first injection. The women will be followed for 20 months after the initial vaccination to determine whether the candidate vaccine prevents HSV infection or disease. Robert B. Belshe, M.D., of NIAID's Vaccine Evaluation and Treatment Unit at the Saint Louis University School of Medicine, will co-ordinate the clinical investigation.

The GSK vaccine is a subunit vaccine containing a piece of the HSV outer coat along with adjuvants, which help boost the immune system for a better response. Women between the age of 18 and 30 who wish to be evaluated for possible inclusion in the trial should visit http://www.niaid.nih.gov/dmid/stds/herpevac/. Persons wishing to learn more about herpes can call the American Social Health Association at 919-361-8488. (Web site: http://www.ashastd.org).

NIAID is a component of the National Institutes of Health (NIH), which is an agency of the Department of Health and Human Services. NIAID supports basic and applied research to prevent, diagnose, and treat infectious and immune-mediated illnesses, including HIV/AIDS and other sexually transmitted diseases, illness from potential agents of bioterrorism, tuberculosis, malaria, autoimmune disorders, asthma and allergies.

Reference: LR Stanberry et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. The New England Journal of Medicine 347:1652-61 (2002).

Press releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.


Story Source:

The above story is based on materials provided by NIH/National Institute Of Allergy And Infectious Diseases. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Institute Of Allergy And Infectious Diseases. "Major Herpes Vaccine Trial Launched In Women." ScienceDaily. ScienceDaily, 21 November 2002. <www.sciencedaily.com/releases/2002/11/021121064940.htm>.
NIH/National Institute Of Allergy And Infectious Diseases. (2002, November 21). Major Herpes Vaccine Trial Launched In Women. ScienceDaily. Retrieved September 3, 2014 from www.sciencedaily.com/releases/2002/11/021121064940.htm
NIH/National Institute Of Allergy And Infectious Diseases. "Major Herpes Vaccine Trial Launched In Women." ScienceDaily. www.sciencedaily.com/releases/2002/11/021121064940.htm (accessed September 3, 2014).

Share This



More Health & Medicine News

Wednesday, September 3, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Snack Attack: Study Says Action Movies Make You Snack More

Snack Attack: Study Says Action Movies Make You Snack More

Newsy (Sep. 2, 2014) You're more likely to gain weight while watching action flicks than you are watching other types of programming, says a new study published in JAMA. Video provided by Newsy
Powered by NewsLook.com
U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Doctors Fear They're Losing Battle Against Ebola

Doctors Fear They're Losing Battle Against Ebola

AP (Sep. 2, 2014) As a third American missionary is confirmed to have contracted Ebola in Liberia, doctors on the ground in West Africa fear they're losing the battle against the outbreak. (Sept. 2) Video provided by AP
Powered by NewsLook.com
Tech Giants Bet on 3D Headsets for Gaming, Healthcare

Tech Giants Bet on 3D Headsets for Gaming, Healthcare

AFP (Sep. 2, 2014) When Facebook acquired the virtual reality hardware developer Oculus VR in March for $2 billion, CEO Mark Zuckerberg hailed the firm's technology as "a new communication platform." Duration: 02:24 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins